- Guide to PHARMACOLOGY
Compound class: Synthetic organic
Comment: AC430 is an investigational, potent and selective small molecule inhibitor of janus kinase 2 (JAK2) being developed by Ambit (now owned by Daiichi Sankyo) for the treatment of cancer and autoimmune diseases. AC430 is the (R) optical isomer claimed in patent US8703943 , although the (S) isomer and racemate are also discussed in the patent descriptions.
1. Holladay MW, Setti E. (2014)
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof.
Patent number: US8703943. Assignee: Ambit Biosciences Corporation. Priority date: 01/09/2010. Publication date: 22/04/2014.